PT-141 (Bremelanotide) 3 month supply

Indications: PT-141 is a specialized peptide therapy that may be incorporated into a supervised patient treatment plan when prescribed by a licensed provider.
Mechanism of Action: It functions as a non-selective melanocortin receptor agonist. Rather than acting on the vascular system, it acts directly on the central nervous system to bind with receptors in the hypothalamus to modulate targeted neural responses.
Clinical Evaluation: A full clinical assessment is required prior to initiation. Ongoing medical supervision ensures the therapy remains aligned with the patient’s individual clinical profile.